Gossamer Bio completes early settlement of convertible notes exchange Jun 5, 2026 06:09AM
Gossamer Bio reports 90.5% participation in convertible note exchange Jun 3, 2026 08:01AM
Gossamer Bio Inc. (GOSS) Misses Q1 EPS by 3c May 18, 2026 07:51AM
Gossamer Bio launches debt exchange offer to eliminate $120 million May 18, 2026 07:06AM
Cantor Fitzgerald Downgrades Gossamer Bio Inc. (GOSS) to Neutral Mar 23, 2026 03:12AM


Mar 17, 2026 04:13PM Gossamer Bio Inc. (GOSS) Misses Q4 EPS by 2c, Beats on Revenue
Feb 24, 2026 07:03AM Wedbush Downgrades Gossamer Bio Inc. (GOSS) to Neutral
Feb 24, 2026 04:34AM Barclays Downgrades Gossamer Bio Inc. (GOSS) to Underweight
Feb 24, 2026 12:43AM Leerink Partners Downgrades Gossamer Bio Inc. (GOSS) to Market Perform
Feb 23, 2026 07:59AM Gossamer Bio Inc. (GOSS) Halted, News Pending
Feb 4, 2026 05:05AM Increasing unusual put option volume: XLB STNE CSGP ARES XPO ZSL GOSS IGV CTSH
Feb 2, 2026 10:49AM Increasing unusual call option volume: ECH MOD ZSL JBS BXSL GOSS TRX AQST IRE BRBR
Jan 28, 2026 04:23PM Gossamer Bio Inc. (GOSS) files mixed shelf
Jan 22, 2026 07:45AM Gossamer Bio (GOSS) Reiterated at Overweight by Cantor Fitzgerald: Phase 3 Readout in Feb
Jan 22, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
Nov 13, 2025 07:29AM Gossamer Bio's (GOSS) Seralitinib Data Likely Comes Out by Feb - Cantor Fitzgerald
Nov 5, 2025 05:49PM Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 2c
Sep 26, 2025 04:45AM Goldman Sachs Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
Sep 16, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
Sep 15, 2025 02:00AM This name is facing a 'major underappreciated data catalyst' says UBS
Sep 11, 2025 10:00AM Increasing unusual call option volume: SPHR SNPS GOSS OPAD SWBI SNDK LDI HIVE PACS RZLV PSQH
Sep 11, 2025 06:49AM Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
Sep 10, 2025 04:17AM UBS Upgrades Gossamer Bio Inc. (GOSS) to Buy
Aug 19, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
May 16, 2025 06:45AM Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
May 15, 2025 04:02PM Gossamer Bio Inc. (GOSS) Tops Q1 EPS by 3c
Mar 18, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
Mar 13, 2025 05:34PM Gossamer Bio Inc. (GOSS) Tops Q4 EPS by 2c
Feb 3, 2025 07:01AM Gossamer Bio (GOSS) Presented Clinical and Preclinical Data
Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
Nov 8, 2024 06:31AM Gossamer Bio Inc. (GOSS) Tops Q3 EPS by 1c
Sep 18, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
Sep 12, 2024 07:43AM Piper Sandler Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025
Aug 30, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
Aug 12, 2024 04:22PM Gossamer Bio Inc. (GOSS) Misses Q2 EPS by 29c
Jul 15, 2024 08:44AM Piper Sandler Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)